Lifeboat Foundation

In a groundbreaking study, researchers have unlocked a new frontier in the fight against aging and age-related diseases. The study, conducted by a team of scientists at Harvard Medical School, has published the first chemical approach to reprogram cells to a younger state. Previously, this was only achievable using a powerful gene therapy.

The team’s findings build upon the discovery that the expression of specific genes, called Yamanaka factors, could convert adult cells into induced pluripotent stem cells (iPSCs). This Nobel Prize-winning discovery raised the question of whether it might be possible to reverse cellular aging without causing cells to become too young and turn cancerous.

Continue reading “US scientists discover chemical to reverse aging” »

Following the success of its first experiment.com campaign, which was raising money to identify therapeutics that reduce senescent cell accumulation and extend healthspan, the SENS Research Foundation has announced the next funding project.

Last month, we covered the fundraiser for Dr Abdelhadi Rebbaa’s research into the discovery and testing of novel senolytic molecules, which would back into his discovery of potential anti-senescence therapeutics. SRF has confirmed that this campaign is now fully funded.

Now SENS Research Foundation has launched its second experiment.com campaign for Dr Amutha Boominathan’s project Finding a cure for mitochondrial DNA diseases through COX2 variations to restore cell function, hoping to raise $8,000 over 45 days, with the campaign coming to an end next month, on 30th August. Dr Boominathan is head of the MitoSENS program at SENS Research Foundation.

Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified potential new biomarkers that could indicate how someone diagnosed with metastatic melanoma will respond to immunotherapy treatment.

The researchers found when T cells are activated, they release a protein called CXCL13, which helps attract more B cells and T cells to the tumor site. The B cells then show the T cells specific parts of the tumor, which leads to increased activation of the T cells and their ability to fight the cancer. This cooperation between T cells and B cells was associated with improved survival in patients diagnosed with metastatic melanoma who were treated with immunotherapy, but not for those who received targeted therapy (e.g., MEK inhibitors).

These findings could help guide new strategies to improve the effectiveness of melanoma cancer treatments. The research is published in the journal Frontiers in Immunology.

USDA found Neuralink to be in compliance with animal safety and welfare standards after an isolated incident of using an unapproved sealant to close a monkey’s skull in a surgery triggered an investigation. FDA granted a request to begin testing it’s implant device in humans.

July 19 (Reuters) — The head of the U.S. agency responsible for animal welfare has told lawmakers that it did not find any violations of animal research rules at Elon Musk’s Neuralink beyond a 2019 incident the brain implant company had already reported.

Officials with the Department of Agriculture (USDA) conducted a “focused” inspection in response to a complaint about the company’s handling of animal experiments, but identified no compliance breaches, the agency’s secretary Thomas Vilsack wrote to Congressman Earl Blumenauer in a July 14 letter reviewed by Reuters.

Continue reading “Regulator says found no animal welfare breaches at Musk firm beyond 2019 incident” »

Griffith University researchers have played a key role in using DNA “origami” templates to control the way viruses are assembled.

The global team behind the research, titled “DNA-origami-directed virus capsid polymorphism,” published in Nature Nanotechnology, developed a way to direct the assembly of virus capsids—the protein shell of viruses—at physiological conditions in a precise and programmable manner.

Dr. Frank Sainsbury and Dr. Donna McNeale from the Griffith Institute for Drug Discovery were part of the research team and said forcing viruses to assemble onto DNA folded into different shapes “like origami” was a question that this project answered.

Blood clots can be deadly medical emergencies that can form in different parts of your body. Learn the warning signs that you might have one.

Akash Ingale, was admitted to Fortis Hospital, Vashi, diagnosed with the unusual combination of Myasthenia Gravis and Thymoma. Myasthenia Gravis is a chronic autoimmune neuromuscular disease causing muscle weakness, typically affecting older individuals, making it rare in young patients like Akash. Moreover, the presence of Thymoma in conjunction with Myasthenia Gravis is even rarer, occurring in only 10–12% of cases. For the past eight months, Akash faced significant mobility challenges, severely impacting his quality of life. Managing the conditions required him to be on multiple drug regimens, including steroids and immunosuppressants, further affecting his well-being.

In this video, Dr Prriya Eshpuniyani, Consultant-Thoracic OncoSurgeon Fortis Hospital, Vashi, Navi Mumbai talks about case history, challenges, prognosis.